Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta

This article was originally published in The Pink Sheet Daily

Executive Summary

Amylin claims Lilly has breached its agreement to commercialize exenatide as the Big Pharma gears up to launch the Boehringer-developed diabetes drug Tradjenta.
Advertisement

Related Content

With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
Lilly Blocked From Selling Boehringer's Tradjenta Until At Least May 31
Lilly Blocked From Selling Boehringer's Tradjenta Until At Least May 31
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors

Topics

Advertisement
UsernamePublicRestriction

Register

PS072239

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel